Rockwell Medical Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Rockwell Medical şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-10.3%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-10.3%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Rockwell Medical, Inc.'s (NASDAQ:RMTI) 28% Dip In Price Shows Sentiment Is Matching Revenues

Nov 15

Rockwell Medical, Inc. (NASDAQ:RMTI) Analysts Just Trimmed Their Revenue Forecasts By 15%

Nov 14

The Market Lifts Rockwell Medical, Inc. (NASDAQ:RMTI) Shares 28% But It Can Do More

Sep 29

Rockwell Medical: The Turnaround Is Looking Real

Sep 15

Rockwell Medical, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates

Aug 11

An Intrinsic Calculation For Rockwell Medical, Inc. (NASDAQ:RMTI) Suggests It's 46% Undervalued

Sep 02

Rockwell Medical Q2 Earnings Preview

Aug 12

Rockwell Medical: Triferic Remains Key Despite Sluggish Growth Profile

Mar 02

Rockwell Medical: Down But By No Means Out

Oct 05

Rockwell Medical pops 6% on licensing deal for Triferic AVNU in Turkey

Jun 08

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: RMTI şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: RMTI şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Rockwell Medical Piyasaya Karşı Temettü Getirisi

RMTI temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (RMTI)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Medical Equipment)	1.6%
Analist tahmini (RMTI) (3 yıla kadar)	n/a

Önemli Temettü: RMTI şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, RMTI şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: RMTI şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: RMTI herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Rockwell Medical Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Independent Director recently sold US$70k worth of stock

Rockwell Medical, Inc.'s (NASDAQ:RMTI) 28% Dip In Price Shows Sentiment Is Matching Revenues

Forecast breakeven date moved forward to 2024

Rockwell Medical, Inc. (NASDAQ:RMTI) Analysts Just Trimmed Their Revenue Forecasts By 15%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Rockwell Medical, Inc. to Report Q3, 2024 Results on Nov 11, 2024

The Market Lifts Rockwell Medical, Inc. (NASDAQ:RMTI) Shares 28% But It Can Do More

Rockwell Medical: The Turnaround Is Looking Real

New minor risk - Share price stability

Rockwell Medical, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Rockwell Medical, Inc. Provides Sales Guidance for the Year 2025 and Beyond

Rockwell Medical, Inc. Launches Convenience Pack to Support Home Hemodialysis and Acute Dialysis Facilities

Rockwell Medical, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Rockwell Medical, Inc.'s (NASDAQ:RMTI) Subdued P/S Might Signal An Opportunity

New major risk - Financial position

Rockwell Medical, Inc. Promotes Tim Chole to Chief Commercial Officer

Consensus EPS estimates fall by 35%, revenue upgraded

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Rockwell Medical, Inc. Revises Earnings Guidance for the Year 2024

Does Rockwell Medical (NASDAQ:RMTI) Have A Healthy Balance Sheet?

Rockwell Medical, Inc. to Report Q1, 2024 Results on May 14, 2024

Rockwell Medical, Inc., Annual General Meeting, May 21, 2024

Consensus EPS estimates upgraded to US$0.10 loss, revenue downgraded

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations

Rockwell Medical, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Is Rockwell Medical (NASDAQ:RMTI) A Risky Investment?

Rockwell Medical, Inc. Provides Earnings Guidance for Fourth Quarter and Full-Year 2023

Rockwell Medical, Inc. (NASDAQ:RMTI) Doing What It Can To Lift Shares

New major risk - Financial position

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rockwell Medical, Inc. Provides Financial Guidance for the Year 2023

Rockwell Medical, Inc. Appoints Jesse Neri as Senior Vice President, Finance

Rockwell Medical, Inc. Appoints Joan Lau, Ph.D. to the Company's Board of Directors

Rockwell Medical, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Is Rockwell Medical (NASDAQ:RMTI) Using Too Much Debt?

Forecast to breakeven in 2025

Rockwell Medical, Inc. Announces Resignation of as Senior Vice President, Finance and Chief Accounting Officer

Consensus EPS estimates fall by 23%

Rockwell Medical, Inc. Revises Financial Guidance for the Year 2023

Second quarter 2023 earnings: EPS misses analyst expectations

Consensus estimates of losses per share improve by 15%

Rockwell Medical, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Rockwell Medical, Inc. (NasdaqCM:RMTI) agreed to acquire Substantially All Assets of Evoqua Water Technologies LLC for $16 million.

New major risk - Share price stability

Is Rockwell Medical (NASDAQ:RMTI) Weighed On By Its Debt Load?

Consensus estimates of losses per share improve by 13%

Rockwell Medical, Inc. Provides Revenue Guidance for Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Rockwell Medical, Inc. to Report Q4, 2022 Results on Mar 30, 2023

Price target decreased to US$5.00

Rockwell Medical, Inc. Provides Earnings Guidance for the Full Year 2022

Is There Now An Opportunity In Rockwell Medical, Inc. (NASDAQ:RMTI)?

Rockwell Medical, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Rockwell Medical, Inc. Names Heather Hunter as SVP, Chief Corporate Affairs Officer

An Intrinsic Calculation For Rockwell Medical, Inc. (NASDAQ:RMTI) Suggests It's 46% Undervalued

Consensus estimates of losses per share improve by 24%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Rockwell Medical Q2 Earnings Preview

Rockwell Medical, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Price target decreased to US$19.00

Rockwell Medical, Inc. Provides Clinical Update

Rockwell Medical, Inc. announced that it has received $14.9 million in funding

Rockwell Medical Regains Compliance with Nasdaq Listing Requirements

Rockwell Medical, Inc. Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial

Rockwell Medical, Inc. to Report Q1, 2022 Results on May 16, 2022

Rockwell Medical, Inc. Announces Completion of Patient Enrollment Ahead of Schedule in Pivotal Phase 3 Clinical Trial of Triferic(R) in China

Rockwell Medical, Inc. announced delayed annual 10-K filing

Rockwell Medical: Triferic Remains Key Despite Sluggish Growth Profile

Forecast to breakeven in 2023

Price target decreased to US$4.00

Rockwell Medical Receives Important Feedback from FDA on Its IND Application for Phase 2 Trial of Ferric Pyrophosphate Citrate in Home Infusion